Percutaneous closure of the left atrial appendage for prevention of thromboembolism in atrial fibrillation for patients with contraindication to or failure of oral anticoagulation: A single-center experience;Encerramento percutâneo do apêndice auricular esquerdo para profilaxia de tromboembolismo na fibrilhação auricular em doentes com contraindicação ou falência da hipocoagulação oral: Experiência de um servico

Revista Portuguesa de Cardiologia

Volumn 32, Issue 6, 2013, Pages 461-471

  Faustino, Ana ^a   Paiva, Lus ^a   Providência, Rui ^a   Trigo, Joana ^a   Botelho, Ana ^a   Costa, Marco ^a   Leitão Marques, António ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Atrial fibrillation; Cardiac implant; Left atrialappendage; Oral anticoagulation; Stroke; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ENOXAPARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG CONTRAINDICATION; DRUG TREATMENT FAILURE; FALSE ANEURYSM; FEMORAL ARTERY; FOLLOW UP; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; ORAL BLEEDING; PHARYNX HEMORRHAGE; POSTOPERATIVE COMPLICATION; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TRANSTHORACIC ECHOCARDIOGRAPHY;

ACIDENTE VASCULAR CEREBRAL; ANTICOAGULAÇÃO ORAL; APÊNDICE AURICULAR ESQUERDO; ATRIAL FIBRILLATION; CARDIAC IMPLANT; FIBRILHAÇÃO AURICULAR; IMPLANTE CARDÍACO; LEFT ATRIAL APPENDAGE; ORAL ANTICOAGULATION; STROKE; THROMBOEMBOLISM; TROMBOEMBOLISMO;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; FEMALE; HUMANS; MALE; PROSTHESIS DESIGN; SEPTAL OCCLUDER DEVICE; THROMBOEMBOLISM; TREATMENT FAILURE;

EID: 84888346321     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.repc.2012.10.011     Document Type: Article

References (28)

1. Bonhorst D, Mendes M, Adragão P, et al. Prevalência de fibrilhação auricular na populacão portuguesa com 40 ou mais anos. Estudo FAMA. Rev Port Cardiol. 2010;29:331-50.
2. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.
3. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: Executive summary. Eur Heart J. 2007;28:2803-17.
4. Contractor T Khasnis A. Left atrial appendage closure in atrial fibrillation: A world without anticoagulation? Cardiol Res Pract. 2011;2011:1-7.
5. Sievert H, Bayard YL. Percutaneous closure of the left atrial appendage: A majot step forward. JACC Cardiovasc Interv. 2009;2:601-2.
6. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: Report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31:967-75.
7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67.
8. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised noninferiority trial. Lancet. 2009;374:534-42.
9. Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF (WATCHMAN left atrial appendage system for embolic PRO-TECTion in patients with atrial fibrillation) trial. Am Heart J. 2006;151:956-61.
10. Cairns JA, Connolly S, McMurtry S, et al., CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: Prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27:74-90.
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
12. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.
13. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92.
14. Fuller CJ, Reisman M. Stroke prevention in atrial fibrillation: Atrial appendage closure. Curr Cardiol Rep. 2011;13:159-66.
15. Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke. 2007;38:624-30.
16. Connolly S, Progue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet. 2006;367:1903-12.
17. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-9.
18. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411-20.
19. Faustino A, Paiva L, Providência R, et al. Encerramento percutâneo do apêndice auricular esquerdo para profilaxia de tromboembolismo na fibrilhacão auricular. Rev Port Cardiol. 2012, http://dx.doi.org/10.1016/j.repc.2012.06.017.
20. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: Early clinical experience. Circulation. 2002;105:1887-9.
21. Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: Initial European experience. Cathet Cardiovasc Interv. 2011;77:700-6.
22. Amplatzer Cardiac Plug Clinical Trial (ACP). Disponível em: www.clinicaltrials.gov/identificador: NCT01118299 [consultado 21 Fev 2012].
23. Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: Results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011;123:417-24.
24. ASA Plavix feasibility study with WATCHMAN left atrial appendage closure technology. Disponível em: www.clinicaltrials.gov/identificador:NCT00851578 [consultado 27 Fev 2012].
25. Reddy V, Neuzil P, Miller MA, et al. First formal analysis of the ASA Plavix Registry (ASAP): Watchman left atrial appendage closure in atrial fibrillation patients with contraindication to oral anticoagulation. Heart Rhythm Society 2012 Scientific Sessions-Late breaking abstract session, Friday, May 11, 2012; Boston, MA. Abstract LB02-2. Disponível em: http://www.hrsonline.org/Education-Meetings/Scientific-Sessions/Past-Scientific-Sessionsxzz2PW5gy68R [consultado 4 Abr 2013].
26. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: Results from the international multi-center feasibility trials. J Am Coll Cardiol. 2005;46:9-14.
27. Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: A PROTECT AF (Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation) substudy. J Am Coll Cardiol. 2012;59:923-9.
28. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2007;49:1490-5.